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The vasculature of the skeletal system regulates osteogenesis and hematopoiesis, in addition to its pri-
mary function as a transportation network. Recent studies suggest that the vasculature in bone regulates
multiple steps involved in the metastatic cascade. Matrix and growth factor abundant vascular micro-
environments in bone not only provide a fertile soil for the metastatic growth but also support the
dormancy of Disseminated Tumour Cells (DTCs). Interestingly, vasculature also seems to direct the re-
activation of dormant DTCs. Targeting such early steps of bone metastasis by directing therapies against
vascular niches can lead to the development of effective therapeutic strategies that delay or even prevent
the metastatic relapse. However, this would require a detailed understanding of the regulatory me-
chanisms that govern the interaction between endothelial cells and DTCs in the early stages of bone
metastasis. This review aims to highlight the importance of vascular niches and outline their newly
identiﬁed roles during bone metastasis.
& 2016 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The skeleton is the most prevalent site of metastasis for several
cancer types. Skeletal metastasis is associated with a reduced
quality of life owing to prolonged pain, poor therapeutic success
and low survival rate [1,2]. The initial stages that underpin this
poor outcome is laid by the extravasation and lodging of circu-
lating tumour cells in the bone marrow microenvironment, a
process that in most patients precedes the primary tumour de-
tection. Disseminated tumour cells (DTCs) may survive within the
bone marrow microenvironment in the state of dormancy (cell
cycle arrest) for very long periods. While a subset of patients de-
velop detectable metastases as late as two-to-three decades post
primary tumour detection, others show no signs of relapse despite
the detection of DTCs in bone postmortem [2–4]. Such clinical
evidence argue in favor of targeting DTCs within the bone mi-
croenvironment, rather than targeting the initial steps of tumour
cell extravasation and dissemination. Designing strategies to target
DTCs within the bone marrow microenvironment is likely to fa-
cilitate the development of therapeutic regimes that delay or
prevent metastatic relapse. However, this requires fundamental
understanding of the mechanisms that lead to dormancy andis an open access article under the
mpg.de,subsequent reactivation of cancer cells. Existing therapeutic stra-
tegies target and slow down progression in the late stage of the
disease; but these therapies are not curative [1–4]. Despite its
tremendous impact on the therapeutic outcome, our under-
standing of the early stage (survival, quiescence, migration and
proliferation of cancer cells in bone) of the disease remains poor.
Multiple lines of evidence demonstrate that tumour cells are
regulated in a non-cell-autonomous manner. Notably, recent
ﬁndings highlight the important roles of the microenvironment in
determining the fate of DTCs [5,6].
Extensive vascularization of the skeletal tissue suggests the
importance of blood vessels in regulating its physiological func-
tions. Endothelium, the innermost cellular layer of blood vessels
forms a central component of the bone marrow vascular micro-
environment [7]. Recent evidence support that a pivotal role is
played by the vascular niche during the early stages of bone me-
tastasis [5]. During the later stages of the disease, blood vessels
enhance the metastatic outgrowth by mediating the delivery of
oxygen, nutrients and growth factors. This implies that altering the
vascular microenvironment of DTCs during the early stages of
metastasis can lead to the elimination of DTCs; thereby preventing
the relapse, while targeting the vasculature at the later stages can
slow down the metastatic growth. This review highlights the
signiﬁcance of vascular niches during skeletal metastases and
discusses the potential therapeutic interventions for targeting the
vascular niche.CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Organ speciﬁcity of the vasculature and heterogeneity among
vascular beds has been suggested to guide the differential extra-
vasation of tumour cells to various organs. Therefore, under-
standing the morphological, cellular, molecular and functional
properties of the bone vasculature is critical for deciphering the
role of the vascular niche during skeletal metastases [8]. Like
vascular beds in other organs, endothelial cells in the skeletal
system are also organized as a widespread hierarchical network of
blood vessels that perform multiple functions. Apart from being a
transport network, blood vessels in the skeletal system provide
inductive signals to regulate skeletal development, homeostasis
and remodeling [7]. Emerging studies reveal that the vasculature
of the skeletal system plays crucial roles in osteogenesis (bone
formation) and haematopoiesis through direct cellular interactions
and paracrine (angiocrine) signalling pathways [9–11]. Haemato-
poietic Stem Cells (HSCs) are frequently detected within vascular
microenvironments, which involve different vessel subtypes
comprising of both endothelial and perivascular cells. Speciﬁc
vascular microenvironments are required to support HSC homing,
self-renewal and quiescence [10]. The skeletal vascular micro-
environment is thus often denoted as the “bone-marrow vascular
niche”. Consequently, there has been a tremendous interest in
understanding the structural and functional properties of the
skeletal endothelium. However, the progress has been hampered
by the lack of understanding of the precise organization of the
vasculature. Bone vasculature is vaguely deﬁned as a network of
sinusoids and arterioles. The discontinuous and fenestrated sinu-
soidal endothelium constitutes the predominant vascular surface
in the skeletal system [12]. We have recently unravelled the fun-
damental aspects of the basic hierarchical organization of bone
arteries, capillaries and veins. We found that the molecular sig-
nature, metabolic activity and functional properties vary between
metaphysis and diaphysis blood vessels. In addition, we have
identiﬁed and characterized a distinct capillary and endothelialFig. 1. Organization of blood vessels in bone. Tile scan confocal images showing metaph
for CD31 (green), Endomucin (red) and α-SMA (white). Linear CD31hi/Endomucinhi type H
sinusoidal endothelium (type L) forms the predominant vascular surface in the diaphysis.
to type H capillaries but not to type L blood vessels. Dashed lines mark the growth plate
interpretation of the references to color in this ﬁgure legend, the reader is referred to tcell subpopulations, one of which (termed type H) plays critical
roles in the regulation of osteoprogenitor cells and thereby bone
formation [9,11].
Different vessel subtypes have distinct functional roles in the
vertebrate skeletal system. Veins drain the sinusoids and type H
capillaries, while arteries deliver oxygen-rich blood and terminate
into the type H capillaries. Columnar type H capillaries oriented
towards the growth plate are characterized by high expression of
markers CD31 and Endomucin and are physically connected to
distal arterioles in the metaphysis and endosteum of long bone
(Fig. 1). Type H capillaries are surrounded by bone-forming os-
teoprogenitor cells and release pro-osteogenic growth factors. In
contrast, type L (CD31lo Endomucinlo) blood vessels, which cor-
respond to the highly branched network of sinusoidal en-
dothelium of the bone marrow cavity, are not directly connected to
arterioles and lack association with bone forming osteoprogenitor
cells [9,11]. Such unique properties of the bone vasculature com-
bined with its heterogeneous nature and expression of growth
factors suggest the existence of distinct microenvironments in
bone which may support the early events during skeletal metas-
tasis and can also accelerate disease progression in the late stage.3. Dissemination-permissive characteristics of the BM vascular
niche
Sinusoids (type L capillaries) are the most abundant blood
vessels in bone and widely distributed throughout the bone
marrow cavity [8]. Sinusoids in bone are discontinuous single layer
of endothelial cells devoid of pericytes. Due to the absence of a
consistent vessel wall and low level expression of tight junction
molecules, sinusoidal endothelium is highly permeable in nature
[8]. Additionally, the sinusoidal wall is specialized to facilitate easy
two-way trafﬁcking of hematopoietic cells [8]. These character-
istics of bone sinusoids are known to expedite invasion, extra-
vasation and docking of circulating tumour cells within the boneysis (mp) and diaphysis (dp) regions of the mouse long bone (tibia) immunostained
blood vessels are abundant in the metaphysis while a highly branched network of
CD31hi (green) Endomucin arteries with α-SMAþ coverage are directly connecting
(gp) and compact bone. Chondrocytes; ch. Nuclei are stained with DAPI (blue). (For
he web version of this article.)
Fig. 2. Bone marrow vascular niches regulate the fate of DTCs. The morphological, structural, adhesive and paracrine/angiocrine properties of the skeletal vasculature guide
the dissemination of cancer cells to bone. Especially, vascular microenvironments in bone are exceptionally rich in extracellular matrix (ECM) proteins, growth factors like
SCF and chemokines like CXCL12. Due to the absence of a consistent vessel wall sinusoidal endothelium is highly permeable and specialized to facilitate easy trafﬁcking of
haematopoietic cells. Circulating tumour cells (CTCs) commandeer HSC homing pathways to land on the bone marrow microenvironment (A). Subsequent to the successful
landing of cancer cells into the bone marrow microenvironment these cells rarely proliferate instantly. DTCs exposed to the unfamiliar bone microenvironment survive in the
dormant state and are frequently detected in close proximity to the vasculature. Endothelial cells from mature blood vessels secrete dormancy inducing factors like TSP1 and
CXCL12 and thereby maintain DTCs in the dormant state (B). Interestingly, in contrast to the stable mature vasculature, sprouting vasculature reactivates (detected as Ki67
positive; a proliferation marker) dormant DTCs through the production of factors like periostin (POSTN) and transforming growth factor β-1 (TGFβ-1). Thus the vasculature of
the skeletal system not only maintains the dormancy of DTCs but also drives the reactivation of dormant DTCs. Once reactivated and a micrometastasis is generated it
promotes blood vessel ingrowth by the production of angiogenic factors further enhancing the metastatic growth (C).
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vessels have exceptionally large diameter [8]. As a result of the
large diameter and voluminous nature of these sinusoidal vessels,
blood ﬂow within bone is reduced dramatically. This leads to
trapping and arrest of circulating tumour cells in the skeletal
system [5,13]. Furthermore, the expression proﬁle of the skeletal
vasculature is largely different as compared to blood vessels in
other tissues. Of note, the vasculature in bone expresses and se-
cretes high levels of CXCL12 (stromal cell-derived factor-1 (SDF-
1)), a member of the CXC family of chemokines, which is known to
play a key role in homing and retention of HSCs in the bone
marrow microenvironment [14]. High levels of these ligands might
draw the circulating tumour cells expressing its receptor, CXCR4 to
the bone (Fig. 2A). Therefore, circulating tumour cells comman-
deer HSC homing pathways to land and establish their footholds
within the foreign bone marrow microenvironment. Other players
in HSC homing pathways are also predicted to be hijacked by DTCs
to facilitate their landing in bone such as matrix molecules like
integrin family members, and adhesion molecules like E-selectin
and Robo4 [15]. Thus, the morphological, structural, adhesive and
paracrine/angiocrine properties of the skeletal vasculature appear
to direct the dissemination of cancer cells to bone.4. Dormancy-conducive characteristics of the BM vascular
niche
Cancer cells ingression into the bone vasculature and their
admission within the marrow cavity does not guarantee their re-
tention and subsequent colonization in bone. Even though manycancer cells circulate through bone and succeed in entering the
bone marrow cavity, only a few persist for metastatic colonization.
Subsequent to their successful landing, cancer cells rarely pro-
liferate instantly (Fig. 2B). These DTCs now exposed to the un-
familiar bone microenvironment, survive in the so-called dormant
(quiescent/growth-arrested) state for long time period. Recent
studies suggest that signals and pathways governing HSC quies-
cence are also involved in maintaining the dormancy of cancer
cells in bone [14,15]. Quiescent HSCs have been found in close
proximity to the vasculature and vascular niches are crucial for
maintaining HSCs in a quiescent state [10]. Likewise it is possible
that speciﬁc vascular niches regulate the dormancy of cancer cells
in bone. In line with this notion, Ghajar et al. identiﬁed that dor-
mant cancer cells in bone are localized in close proximity to the
stable vasculature [16]. To gain mechanistic insight into this en-
dothelial and cancer cell interactions authors generated in vitro 3D
cultures with human umbilical vein endothelial cells and bone
marrow-derived mesenchymal cells. Cancer cells cultured on this
organotypic microvasculature exhibited reduced proliferation and
growth. Further analysis of the endothelial extracellular matrix
revealed up-regulation of thrombospondin-1 (TSP-1), which was
secreted by endothelial cells, as a suppressor of cancer cell growth.
Antibody driven blocking of TSP-1 to impede cancer cell interac-
tion with endothelium resulted in increased proliferation and
growth of cancer cells. This interesting study provides crucial
mechanistic insights into the regulation of cancer cell dormancy
[16]. Since the study relied on ﬁndings from the in vitro 3D co-
culture system, further research is needed to delineate and un-
derstand the in vivo situation. Another example of angiocrine
factors regulating cancer cell dormancy in bone is the chemokine
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by the bone vasculature may regulate the dormancy of DTCs in
bone [17]. Further, stromal cells in bone also contribute to the
dormancy of tumour cells by secreting microRNAs (miRs) that
target CXCL12 expression. These anti-CXCL12 miRs transported
from stromal cells to breast tumour cells induce cell cycle arrest
[17]. However, it remains unstudied whether endothelial cells also
express these miRs. Similarly, other known regulators of HSC
quiescence in the bone marrow such as growth arrest-speciﬁc
protein 6 (GAS6), transforming growth factor-β2 (TGFβ2), bone
morphogenetic protein 4 (BMP4), BMP7 also induce dormancy of
DTCs [18]. Interestingly, morphogenetic cues like BMPs and TGFβ
family members that induce dormancy in DTCs are expressed by
the bone vasculature. Overall, above studies emphasize the im-
portance of bone endothelial cells in supporting the dormancy of
DTCs (Fig. 2B), though the detailed identity of functional vascular
niches for DTCs remains anonymous.5. Growth-supportive characteristics of the BM vascular niche
Similar to normal tissues, tumours also need functional blood
vessels to support their growth via the delivery of oxygen and
nutrients. When a DTC starts proliferating into a micrometastasis,
it drives angiogenesis to build new blood vessels. If angiogenesis
fails and new vasculature is not recruited, micrometastasis re-
mains deprived of oxygen and nutrients. Consequently, cell death
balances proliferation thereby preventing the development of
clinically detectable metastases [18]. Remarkably, it has been de-
monstrated that while stable vasculature supports dormancy of
DTCs, proliferating cancer cells are selectively localized in close
proximity to the sprouting vasculature (Fig. 2C). In vitro 3D co-
culture experiments with cancer cells and actively growing mi-
crovasculature demonstrated that cancer cell proliferation posi-
tively correlated with the sprouting microvasculature. These neo-
vascular tips were characterized by high expression of periostin,
ﬁbronectin, tenascin, versican, and active transforming growth
factor-β1 (TGF-β1) [16]. All these factors have been previously
implicated to contribute to the development of the metastatic
niche. Further the bone marrow cavity is hypoxic and bone matrix
is exceptionally rich in growth factors, cytokines and bone re-
sorbing factors. Endothelial cells secrete several of these growth
factors including TGFβs, IGFs, FGFs, PDGFs and BMPs. Blocking of
an angiocrine factor – placental growth factor (PlGF), using anti-
mouse-PlGF antibodies, resulted in decreased bone metastasis
[19]. Additional endothelial factors that can stimulate proliferation
and growth of cancer cells in bone include osteopontin, SCF and
CXCL12 [5,10,11]. The hypoxic nature of bone, combined with its
abundant resource of growth factors and cytokines alter the phe-
notype of tumour cells to produce aggressive metastatic lesions.
Above evidences suggest that, interfering with endothelial cell-
cancer cell interactions during early stages of metastatic growth
may lead to the development of effective therapeutic strategies to
delay or even prevent the metastatic relapse.6. Therapeutic targeting of the BM vascular niche
The most encouraging perspective of above observations is the
potential of disrupting cancer cell-endothelial cell interactions and
interfering with the bone marrow vascular niche during the early
stage of the disease to sensitize cancer cells to the therapeutic
regimes. Lessons from hematological malignancies indeed provide
the proof of principle for targeting cancer cell-endothelial cell
interactions [20]. This strategy has led to the successful eradi-
cation of leukaemic stem cells from patients and substantialimprovement in survival rates. Mobilization of cancer cells out of
their niche microenvironments render these cells vulnerable to
chemotherapy. For instance, treatment with a CXCR4 antagonist
AMD3100 sensitizes acute myeloid leukaemic cells to chemother-
apy [20]. Another evidence suggests that endothelial Delta-like 4
(DLL4), a Notch signalling ligand induces exit of dormancy in T-ALL
cells by interacting with NOTCH3 receptors on these cells. More-
over, vascular endothelial growth factor A (VEGFA) promotes
overexpression of DLL4 [18]. Therefore, modulating endothelial
cell-DTC interactions by CXCR4 antagonist or VEGF inhibitors of-
fers the possibility to eradicate dormant DTCs. Even though,
waking dormant tumour cells offers an exciting opportunity to
eradicate them, simultaneous targeting and sensitization of these
cells with existing therapies is the key to a successful outcome and
the disease free survival.7. Concluding remarks
Emerging evidences indicate that vascular niches in bone
control the fate of DTCs and thereby inﬂuence multiple steps
within the metastatic cascade. Our current knowledge of the cel-
lular and molecular mechanisms governing cancer cell dormancy
and subsequent reactivation in bone suggests that DTCs exploit the
molecular machinery used by HSCs to establish their footholds in
bone. Nevertheless, the speciﬁc roles of vascular niches during the
early steps of skeletal metastasis remain little understood. A better
understanding of the DTC-endothelial cell interactions is required
for targeting the early steps of skeletal metastasis. HSC niches have
been shown to be composed of multiple cell populations including
osteoblasts and mesenchymal stem cells. Similarly, the fate of
DTCs in bone may be regulated by complex microenvironments
involving multiple cell populations and vessel subtypes. Char-
acterizing these niches and understanding molecular pathways
coupling the behaviour of DTCs and niche cells can lead to the
development of effective therapeutic strategies that delay or even
prevent the metastatic relapse.References
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